| Followers | 436 |
| Posts | 41282 |
| Boards Moderated | 0 |
| Alias Born | 10/07/2010 |
Wednesday, January 15, 2020 5:56:23 PM
The filing on that deal and why it didn't happen were pretty interesting:
NOTE 13 – ACQUISITION OF LAKE VICTORIA MINING COMPANY
In December 2018, we purchased control of a public shell company, Lake Victoria Mining Company. (“LVCA”), for $150,000 cash, incurred $30,300 of acquisition costs, and which included a noncontrolling interest of $15,085 for a total investment amount of $195,385, through which we intended to effectuate becoming a public company through a reverse merger transaction. The transaction was recorded as an asset acquisition (as we purchased 2,000 authorized unregistered shares of Series L preferred stock, the “Control Shares”) and substantially all of the purchase consideration was allocated to an intangible asset. During the fiscal year ended April 30, 2019, we determined that LVCA was not a suitable entity through which we could accomplish our objective. In addition, we evaluated the impairment indicators including, but not limited to:
a.
An investor would not finance the LVCA transaction due to the fact that it would not be able to take advantage of the SEC Rule 144 exemption as LVCA was not a ‘reporting company
b.
The Control Shares cannot be converted into shares of LVCA’s common stock and do not trade on any exchange or marketplace
c.
There is no liquid market for a voting control block of an OTC pink traded entity with no assets.
d.
When we tried to sell the Control Shares in early May 2019, no buyers emerged, and
e.
A well known broker of public shell companies informed the Company that LVCA was not marketable.
Based on these indicators, we determined that the asset was permanently impaired, and we recorded an impairment charge related to the investment in LVCA of $195,385, leaving a net realizable value of $0 as of April 30, 2019
In July 2019, we sold our investment in LVCA to an entity owned by the CEO and COO of the Company for $1,000 and the assumption of $23,822 of liabilities resulting in an increase in additional paid in capital of $24,822.
NOTE 13 – ACQUISITION OF LAKE VICTORIA MINING COMPANY
In December 2018, we purchased control of a public shell company, Lake Victoria Mining Company. (“LVCA”), for $150,000 cash, incurred $30,300 of acquisition costs, and which included a noncontrolling interest of $15,085 for a total investment amount of $195,385, through which we intended to effectuate becoming a public company through a reverse merger transaction. The transaction was recorded as an asset acquisition (as we purchased 2,000 authorized unregistered shares of Series L preferred stock, the “Control Shares”) and substantially all of the purchase consideration was allocated to an intangible asset. During the fiscal year ended April 30, 2019, we determined that LVCA was not a suitable entity through which we could accomplish our objective. In addition, we evaluated the impairment indicators including, but not limited to:
a.
An investor would not finance the LVCA transaction due to the fact that it would not be able to take advantage of the SEC Rule 144 exemption as LVCA was not a ‘reporting company
b.
The Control Shares cannot be converted into shares of LVCA’s common stock and do not trade on any exchange or marketplace
c.
There is no liquid market for a voting control block of an OTC pink traded entity with no assets.
d.
When we tried to sell the Control Shares in early May 2019, no buyers emerged, and
e.
A well known broker of public shell companies informed the Company that LVCA was not marketable.
Based on these indicators, we determined that the asset was permanently impaired, and we recorded an impairment charge related to the investment in LVCA of $195,385, leaving a net realizable value of $0 as of April 30, 2019
In July 2019, we sold our investment in LVCA to an entity owned by the CEO and COO of the Company for $1,000 and the assumption of $23,822 of liabilities resulting in an increase in additional paid in capital of $24,822.
Recent MAJI News
- NexTel Medical Corp Announces Pivotal Milestone in Commercial Launch of Patent-Protected NANOG DNA Cancer Screening Test • GlobeNewswire Inc. • 04/07/2026 02:30:00 PM
- Form QUALIF - Notice of Qualification [Regulation A] • Edgar (US Regulatory) • 03/30/2026 04:15:02 AM
- Form 253G1 - • Edgar (US Regulatory) • 03/27/2026 07:12:08 PM
- Form 1-A POS - • Edgar (US Regulatory) • 03/26/2026 08:25:15 PM
- Form 1-A POS - • Edgar (US Regulatory) • 03/20/2026 08:23:33 PM
- Exousia Pro, Inc. Announces Favorable Litigation Settlement, Highlighting Significant Debt Elimination and Share Cancellation to Enhance Shareholder Value • GlobeNewswire Inc. • 03/16/2026 02:15:00 PM
- Form 1-A POS - • Edgar (US Regulatory) • 03/11/2026 07:11:39 PM
- Exousia Pro, Inc. Announces Strategic Elimination of Future Dilutive Issuance of 47 Million Shares, Progresses Toward Definitive Agreements for Telehealth Acquisitions • GlobeNewswire Inc. • 03/05/2026 06:00:20 PM
- Form 1-A POS - • Edgar (US Regulatory) • 02/19/2026 09:39:04 PM
- Form 253G2 - • Edgar (US Regulatory) • 02/11/2026 08:06:08 PM
- Exousia Pro, Inc. Accelerates Strategic Expansion with Third Telehealth Acquisition; Strengthens Pathway to Low-Cost Customer Acquisition • GlobeNewswire Inc. • 02/10/2026 03:30:00 PM
- Form 253G2 - • Edgar (US Regulatory) • 01/15/2026 06:47:01 PM
- Form 253G1 - • Edgar (US Regulatory) • 01/14/2026 09:54:45 PM
- Form 1-A POS - • Edgar (US Regulatory) • 12/31/2025 12:32:47 PM
- Form 253G2 - • Edgar (US Regulatory) • 12/29/2025 08:29:49 PM
- Exousia Pro, Inc. Announces Executed LOI for Strategic Acquisition of High-Revenue Telehealth Platform to Accelerate Nutraceutical Commercialization • ACCESS Newswire • 12/11/2025 05:15:00 PM
- Exousia Pro, Inc. Revolutionizes Nutraceuticals With Launch Of Maxasome(TM): The First All-Natural, Biologically Active Exosomal Supplement • ACCESS Newswire • 12/05/2025 04:00:00 PM
- Form 253G2 - • Edgar (US Regulatory) • 12/04/2025 09:35:28 PM
- Exousia Pro, Inc. Completes Exclusive Licensing Agreement With the University of Central Florida for Novel Cancer Diagnostic and Therapy Platforms • ACCESS Newswire • 12/02/2025 06:45:00 PM
- Exousia Pro Initiates Strategic Realignment, Acquires Controlling Stake in SEC-Reporter Lamy (LMMY) in All-stock Exchange Transaction for Exousia AI, to Advance Growth and Enhance Shareholder Value • ACCESS Newswire • 11/17/2025 08:40:00 PM
- Exousia Pro Announces Breakthrough In Exosome-Based Delivery • ACCESS Newswire • 11/04/2025 03:40:00 PM
- Exousia Pro is Excited to Announce that it has Received Orphan Drug Designation from the FDA • ACCESS Newswire • 10/28/2025 02:20:00 PM
- Exousia Pro Announces Groundbreaking Study to Revolutionize the Global Edibles Market with CBD-Loaded Exosomes • ACCESS Newswire • 09/29/2025 04:35:00 PM
- Exousia Pro Reports Positive Outcome in Legal Proceeding • ACCESS Newswire • 09/26/2025 02:30:00 PM
